RE:RE:RE:RE:RE:RE:RE:RE:RE:New Press Release - Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Studygebremeskel wrote: I guess we better cash in our chips fellas. It turns out that Theralase partnering with a big pharma is only an "outlier event" - devoutly to be wished but unlikely in the extreme! And this comes straight from the pen of the Venerable Benedictus himself!
Ah me, Bennie why don't you come right out and say it. Theralase shareholders are screwed!
But of course no one should blame you for your dismal prognistications. You're only bringing some hard nosed reality to the board. And of course you hope you're wrong - that goes without saying!
Benedictus wrote: enriquesuave wrote: A new investor like us longs should think, that this MC is way too low given our accomplishments. Compared to peers such as CGON, $2.6 Billion US, IBRX, $ 2 Billion US, we could go up 50-100 times to catch up in MC value. Short term catalysts are BTD, more data, Licensing agreements with Big Pharma. More preclinical data on GBM or NSCLC for XPDT which in of itself is a potential wirth of many Billions. At $30 million MC vs $2-3 Billion one could think and hope that once BTD is granted, everyone will take TLT seriously. All IMHO
beenthere wrote: That's great but it's coming from an investor who has been here for years and knows much about TLT.
What would you think what a new investor who would know very little about TLT think after reading this news? Would they be interested and dig deeper or think 3 years in the making .. maybe. I think I will pass! At best I might add it to my watch list.
Fully diluted market cap after recent issuance is roughly $68M. Any hoped for catalyst will likely bring all outstanding wts and opts itm since majority are priced at .35 or below, so best to account for the full share structure.
While we'd all really like to see a peer comparable m/c for Theralase, the reality is those peers went to market with strong VC funding leading to institutional capital backing, polished marketing to retail and a reliable liquidity flow on a credible exchange.
Important milestones being achieved will no doubt mean a significant share re-rate from such a low base but only an outlier event like a BP picking this protocol as its chosen partner for commercial advancement would result in Theralase potentially being traded on par with the likes of CGON imo. For now, I'm assuming BTD and even AA will result in sizable re-rates but since institutional capital just doesn't freely flow toward the venture exchange, the m/c will struggle to get to even 50% of the peers you mention. Hopefully I'm wrong about that but even if I am, 50% of $2.5B is still quite some upside.
Another predictable smarmy shoot the messenger post from the gerber playbook. Your us against the naysayers tone is petty and tiresome. If you don't care to read my posts then simply ignore them as many others here have thankfully chosen to do. I imagine it's the ongoing frustration longs have that causes such rude intolerance of any poster who doesn't toe the party line, which just reduces the board to mostly one-sided rose colored bias and self congratulatory snipes at any counter arguments.
Yes, BP partnering with ruvidar is an outlier from my view based on current CR data and where capital is flowing and deals are being done. BTD approval and some sort of licensing deal being closed seem within site possibly this year but a company transformative moment in which BP comes in as suitor and savior is just a shareholder dream at the moment.